Publication: Apomorphine in the treatment of parkinson's disease
dc.contributor.author | Ozkan, Serhat | |
dc.contributor.author | Elibol, Bulent | |
dc.contributor.author | Ozkaynak, Sehur Sibel | |
dc.contributor.author | Cakmur, Raif | |
dc.contributor.author | Akbostanci, Muhittin Cenk | |
dc.contributor.author | Hanagasi, Hasmet | |
dc.contributor.author | Dogu, Okan | |
dc.contributor.buuauthor | Erer, Sevda | |
dc.contributor.buuauthor | ERER ÖZBEK, ÇİĞDEM SEVDA | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı. | |
dc.contributor.orcid | 0000-0002-2274-3230 | |
dc.contributor.researcherid | G-9559-2014 | |
dc.date.accessioned | 2024-06-26T11:30:37Z | |
dc.date.available | 2024-06-26T11:30:37Z | |
dc.date.issued | 2021-12-01 | |
dc.description.abstract | Apomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications during Parkinson's disease, which could be administered as an intermittent or continuous infusion. Although apomorphine treatment has been shown to be effective on motor fluctuations and dyskinesias, there is no sufficient consensus regarding the administration of apomorphine test or infusion, and the management of the treatment. In this review, our aim is to create a "treatment management guideline," which includes recommendations for the use of apomorphine in the clinical practice, and to discuss the problems encountered in both intermittent and continuous infusion applications, in the light of the literature. | |
dc.identifier.doi | 10.4274/tnd.2021.06706 | |
dc.identifier.endpage | 365 | |
dc.identifier.issn | 1301-062X | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 358 | |
dc.identifier.uri | https://doi.org/10.4274/tnd.2021.06706 | |
dc.identifier.uri | https://hdl.handle.net/11452/42439 | |
dc.identifier.volume | 27 | |
dc.identifier.wos | 000740715600001 | |
dc.indexed.wos | WOS.ESCI | |
dc.language.iso | en | |
dc.publisher | Türk Nöroloji Derneği | |
dc.relation.journal | Turkish Journal Of Neurology | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Term follow-up | |
dc.subject | Subcutaneous apomorphine | |
dc.subject | Double-blind | |
dc.subject | Ultrasound treatment | |
dc.subject | Infusion | |
dc.subject | Motor | |
dc.subject | Efficacy | |
dc.subject | Receptor | |
dc.subject | Apomorphine | |
dc.subject | Parkinson's disease | |
dc.subject | Treatment | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Clinical neurology | |
dc.subject | Neurosciences & neurology | |
dc.title | Apomorphine in the treatment of parkinson's disease | |
dc.type | Review | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | fb9c4353-c7bb-4165-951e-f6153aadc524 | |
relation.isAuthorOfPublication.latestForDiscovery | fb9c4353-c7bb-4165-951e-f6153aadc524 |